Select changes in microRNA (miRNA) expression correlate with estrogen receptor a (ERa) expression in breast tumors. miR-21 is higher in ERa positive than negative tumors, but no one has examined how estradiol (E 2 ) regulates miR-21 in breast cancer cells. Here we report that E 2 inhibits miR-21 expression in MCF-7 human breast cancer cells. The E 2 -induced reduction in miR-21 was inhibited by 4-hydroxytamoxifen (4-OHT), ICI 182 780 (Faslodex), and siRNA ERa indicating that the suppression is ERa-mediated. ERa and ERb agonists PPT and DPN inhibited and 4-OHT increased miR-21 expression. E 2 increased luciferase activity from reporters containing the miR-21 recognition elements from the 3'-UTRs of miR-21 target genes, corroborating that E 2 represses miR-21 expression resulting in a loss of target gene suppression. The E 2 -mediated decrease in miR-21 correlated with increased protein expression of endogenous miR-21-targets Pdcd4, PTEN and Bcl-2. siRNA knockdown of ERa blocked the E 2 -induced increase in Pdcd4, PTEN and Bcl-2. Transfection of MCF-7 cells with antisense (AS) to miR-21 mimicked the E 2 -induced increase in Pdcd4, PTEN and Bcl-2. These results are the first to demonstrate that E 2 represses the expression of an oncogenic miRNA, miR-21, by activating estrogen receptor in MCF-7 cells.
INTRODUCTION
Although the precise sequence of events leading to breast tumors are not understood, lifetime exposure to estrogens is widely accepted as a major risk factor for the development of breast cancer. Estrogens promote cell replication by binding to the estrogen receptors a and b (ERa and ERb). Ligand-activated ER acts genomically by binding directly to estrogen response elements (EREs) or by a 'tethering mechanism', e.g. by interacting with AP-1 (1) or Sp1 (2) . These interactions recruit coregulators to initiate chromatin remodeling resulting in increased gene transcription (3) . ER can also suppress target gene transcription, although the mechanisms involved are unresolved (4) . In addition to its ER-mediated, genomic activity, E 2 also has 'non-genomic' or 'membrane-initiated' effects, i.e. independent of ER-mediated transcription, that occur within minutes after estradiol (E 2 ), or other ER ligand, administration (5, 6) .
Inhibition of estrogen action is used as the adjuvant therapy of choice to treat both pre-and post-menopausal women with breast cancer. The anti-estrogen/Selective ER Modulator (SERM) tamoxifen (TAM) is the 'gold standard' of treatment of women with ER positive tumors (7) . TAM is a SERM because it has mixed agonist/antagonist activity in a cell-and gene-specific manner whereas Faslodex (Fulvestrant, ICI 182 780) has pure antiestrogen activity (8) . Ablation of endogenous estrogen production using aromatase inhibitors (AIs, e.g. anastrozole, letrozole and exemestane) has an efficacy greater than TAM in preventing disease recurrence in post-menopausal breast cancer patients (9) . Together, these data demonstrate the importance of endogenous estrogens in promoting breast cancer recurrence.
MicroRNAs (miRNAs) are a class of naturally occurring, small, non-coding RNA molecules distinct from small interfering RNAs (siRNAs) (10) (11) (12) . miRNA genes are mostly transcribed by RNA polymerase II, processed by Drosha into short hairpin RNAs that are exported from the nucleus, and processed by Dicer to form mature 21-25 nucleotide miRNAs which are transferred to Argonaute proteins in RISC. miRNAs bind to the 3 0 -untranslated region (3 0 UTR) of target mRNAs and either block the translation of the message or target the mRNA transcript to be degraded (13) . miRNAs may also increase translation of select mRNAs in a cell cycledependent manner (14) .
The human genome contains >700 miRNAs (15) and miRNAs are expressed in a tissue-specific manner (16) . Each miRNA targets $200 transcripts directly or indirectly (17) . Aberrant patterns of miRNA expression have been reported in human breast cancer . A number of genes involved in breast cancer progression have been identified by in silico analysis to be targets of miRNAs that are deregulated in breast cancer (41) and some, e.g. AIB1 have been experimentally proven (42) . We recently reported that miR-21 downregulates the translation of human PDCD4, a tumor suppressor in MCF-7 cells (43) . Although miR-21 was identified as an 'oncomiR', was the most significantly up-regulated miRNA in breast tumor biopsies (37) , and was significantly higher in ERa+ than ERa-breast tumors (40) , no one has examined whether E 2 or SERMs regulate miR-21 expression in human breast cancer cells.
In this study, we tested the hypothesis that miR-21, an 'oncomiR', is regulated by E 2 in MCF-7 breast cancer cells. Although E 2 increases proliferation of MCF-7 cells, we found that E 2 inhibits miR-21 expression. Experiments were performed to test the effect of E 2 on targets of miR-21. In silico analysis identified miR-21 seed elements in six target genes and these miRNA recognition elements (MREs) were cloned into the 3 0 UTR of a Renilla reporter for subsequent transcriptional evaluation and examination of the effect of antisense to miR-21 on Renilla luciferase. Antisense to miR-21 was used to confirm the importance of miR-21-MRE interaction in response to E 2 . Importantly, the E 2 -mediated decrease in miR-21 correlated with increased expression of miR-21-targets PDCD4, PTEN and Bcl-2 at the protein level. These results identify miR-21 as an E 2 -ER-regulated miRNA in MCF-7 cells.
MATERIALS AND METHODS

Cells and treatments
MCF-7 cells were purchased from ATCC and maintained as previously described (44) . 17b-estradiol (E 2 ), 4-hydroxytamoxifen (4-OHT), Actinomycin D (ActD, a transcriptional inhibitor) and cycloheximide (CHX, a protein synthesis inhibitor) were purchased from Sigma; ICI 182 780 (ICI), 4,4 0 ,4 00 -(4-propyl-[1H]-pyrazole-1,3, 5-triyl)trisphenol (PPT, an ERa-selective agonist) and 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN, an ERbselective agonist) were purchased from Tocris. Prior to ligand treatment, the medium was replaced with phenol red-free IMEM supplemented with 5% dextran charcoalstripped FBS (DCC-FBS) for 48 h (serum-starved). Where indicated, MCF-7 cells were pre-treated with 10 mg/ml ActD or 10 mg/ml CHX, for 1 h before ligand treatment. Cells were treated with ethanol (EtOH, the vehicle control) 0.01% final volume, 10 nM E 2 , 100 nM 4-OHT, 10 nM PPT, or 10 nM DPN, alone or in combination with 100 nM ICI for 6 h. For the indicated experiments, cells were pretreated with 100 nM ICI for 6 h prior to EtOH or E 2 treatment.
miRNA microarray
RNA was isolated from MCF-7 cells treated with EtOH or 10 nM E 2 for 6 h using the mirVana miRNA Isolation Kit from Ambion (Austin, TX) and was sent to LC Sciences (Houston, TX) (http://lcsciences.com/) where the RNA samples were labeled either with Cy3 or Cy5 and were hybridized with two identical, dual-color miRNA microarray chips (MRA-1001, LC Sciences). The array contains probes to detect mature miRNA sequences as well as pre-miRNAs in the Sanger miRNA registry (http://microrna.sanger.ac.uk/sequences/). Each human miRNA on the chip contains seven redundancies for each sequence to increase sensitivity. Microarray analysis was performed by LCS including background subtraction and data normalization to the statistical median of all detectable transcripts. Two lists of differentially expressed transcripts (based on a P-value < 0.01) from two chips were merged into one list and a statistical correlation between the two sets of data was calculated.
Constructs of miRNA-recognition elements (MREs)
For MRE sequences, synthetic DNA oligonucleotides ($35 bp) containing the MRE sequence (Supplementary Table 1 ) and $5 bp adjacent sequences from each end were annealed and ligated into the NotI/XhoI sites located in the 3 0 UTR region of the pRL-TK Renilla luciferase reporter from Promega. Full-length (FL) 3 0 -UTRs of PDCD4 and RASA1 were amplified by PCR and inserted into the phRL-TK vector, similarly. All constructs were confirmed by DNA sequencing.
Quantitative real-time PCR (Q-PCR) analysis of miRNA and mRNA expression miRNA-enriched total RNA was extracted from MCF-7 cells using the mirVana miRNA isolation kit (Ambion). Quantification of miRNAs was performed using TaqMan MicroRNA Assays (Applied Biosystems). U6 RNA was used for normalization of miRNA expression. For analysis of PTEN, PDCD4, BCL2 and TMEM49 mRNA expression, RNA was extracted using Trizol and quantitation was performed using TaqMan primers and probes from ABI using 18S for normalization. Analysis and fold change were determined using the comparative threshold cycle (Ct) method. The change in miRNA or mRNA expression was calculated as fold-change, i.e. relative to EtOH-treated (control).
Western blot
Cells were treated as indicated in individual figure and whole cell extracts (WCE) were prepared in modified RIPA buffer as described (22) . Western analysis was performed and quantitated as described (19) . Membranes were probed with ERa antibodies AER320 from NeoMarkers or HC-20 from Santa Cruz Biotechnology, ERb antibody H150 (Santa Cruz Biotechnology), polyclonal PDCD4 antibody from Genetex, monoclonal PTEN antibody from Cell Signaling, or monoclonal Bcl-2 antibody from Assay Designs. Membranes were stripped and re-probed for b-actin (Sigma). (23) . For Figure 3A , MCF-7 cells were transfected with 250 ng of pmiR-21s-luc or pmiR-21as-luc reporters described in (45) and 5 ng pRL-TK (control). Twenty-four hours after transfection, triplicate wells were treated with EtOH (vehicle control), E 2 , 4-OHT or ICI 182 780 as indicated in the figure legend. The cells were harvested 30 h post-treatment using Promega's Passive Lysis buffer. Luciferase and Renilla luciferase activities were determined using Promega's Dual Luciferase assay. For Figure 2 , Renilla luciferase was normalized by Firefly luciferase to correct for transfection efficiency. For Figure 3A , Firefly luciferase was normalized to Renilla luciferase. Fold induction was determined by dividing the averaged normalized values from each treatment by the EtOH value for each transfection condition within that experiment. Values were averaged from multiple experiments as indicated in the figure legends.
AS-control and AS-miR-21 transfection
MCF-7 cells were transfected with AS-duplexes and control-nonspecific siRNA obtained from Ambion using Lipofectamine RNAiMAX from Invitrogen according to the manufacturer's protocol. Twenty-four hours posttransfection, the medium was replaced with phenol redfree IMEM with 5% DCC for 48 h and the cells were treated with ethanol (EtOH) vehicle control, 10 nM E 2 , 10 nM PPT or 10 nM DPN for 24 h prior. Total RNA was isolated for Q-PCR analysis and WCEs were prepared and stored for 24 h at À808C until western blot analysis. Each experiment was repeated for a total of three biological replicates. Western blots were quantified as above and the ratio of each protein/b-actin in the AS-control in EtOH-treated samples was set to 1 in each experiment.
ERa and ERb knockdown by siRNA
MCF-7 cells were transfected with siRNA duplexes and control-nonspecific siRNA obtained from New England Biolabs (44) . Forty-eight hours post-transfection, the cells were treated with 10 nM E 2 , 10 nM PPT or 10 nM DPN for 6 h for mRNA analysis, or 24 h for protein analysis. Total RNA was isolated for Q-PCR analysis and WCEs were prepared and stored for 24 h at À808C until western blot analysis.
Statistics
Statistical analyses were performed using Student's t-test or one-way ANOVA followed by Student-NewmanKeuls or Dunnett's post-hoc tests using GraphPad Prism (San Diego, CA).
RESULTS
E 2 regulates miR-21 expression in MCF-7 breast cancer cells
Estrogens promote breast tumor development by increasing transcription of protooncogenes and growth factors (46) and by negatively modulating the expression or functional activity of tumor suppressors (47) . To determine the identity of primary E 2 -regulated miRNAs in estrogenresponsive human breast cancer cells, ERa-positive MCF-7 human breast cancer cells were treated with 10 nM E 2 or EtOH (vehicle control) for 6 h. Among the E 2 -down-regulated miRNAs, we selected miR-21 for further evaluation because miR-21 is an oncomiR and its expression is higher in ERa positive versus negative tumors (40) . Furthermore, no one has examined if E 2 regulates miR-21 expression in breast cancer cells. Q-PCR using the TaqMan primer/probe sets from ABI indicated a $60% reduction in mature miR-21 by E 2 ( Figure 1 ). To determine the mechanism by which E 2 reduces miR-21, MCF-7 cells were pre-incubated with 100 nM ICI 182 780 (ICI, Faslodex), a pure antagonist of ER genomic action (48, 49) , or 100 nM 4-OHT, the active metabolite of the antiestrogen tamoxifen, and then treated with E 2 . The effect of 4-OHT or ICI alone was also examined. If E 2 represses miR-21 expression by binding ER, then ICI should block the decrease. Because 4-OHT has mixed ER agonist/antagonist activity in a gene-and cell-specific manner, its effect on miR-21 expression could either mimic or oppose the E 2 effect, reflecting its selective Ã Significantly different from the EtOH control, P < 0.05.
ÃÃ Significantly different from E 2 , P < 0.05.
ER modulator (SERM) agonist/antagonist activity. ICI reduced ERa protein by $30-50% in MCF-7 cells (Supplementary Figure 1) , but had no effect on basal miR-21 expression ( Figure 1 ). 4-OHT increased miR-21, indicating that 4-OHT opposes E 2 -induced miR-21 repression through ER binding. Since both 4-OHT and ICI relieved E 2 suppression of miR-21, this reduction is ER-mediated. Although ERa expression is higher than ERb in MCF-7 cells, both ER subtypes are expressed (44) . To examine the contributions of ERa and ERb to the E 2 -induced reduction in miR-21, MCF-7 cells were treated with 10 nM PPT or 10 nM DPN, concentrations at which each is an ERaor ERb-selective agonist, respectively (50) . PPT and DPN, like E 2 , reduced miR-21 ( Figure 1 ). E 2 did not regulate miR-21 expression in ERa+/ERb+ T47D cells (Supplementary Figure 2) , indicating cell-line-specific differences, similar to previous reports that E 2 responses differ between MCF-7 and T47D cells (51) (52) (53) (54) . Together, these data indicate that both ERa and ERb contribute to miR-21 repression by E 2 .
Effect of E 2 on miR-21 target gene reporter activity in MCF-7 cells
The biological activity of miRNAs is primarily mediated by interaction with matching recognition sequences in the 3 0 UTRs of target genes and reducing translation. A $33-bp region from the 3 0 UTR centering on the putative miR-21 miRNA regulatory element (miRNA recognition elements (MREs), also called a 'seed element', 5 0 -AT AAGCTA-3 0 ), and minimally 4 bp flanking this sequence from the six genes listed in Supplementary Table 1 were cloned into the 3 0 UTR of pRL-TK Renilla reporter plasmid. The pRL-TK-MRE or pRL-TK parental plasmids were transiently transfected into MCF-7 cells with pGL3-pro-luciferase as a control and cells were treated with EtOH or E 2 ( Figure 2A and B) . If E 2 reduces miR-21, we would expect an increase in the expression of Renilla but not Firefly luciferase activity since repression would be relieved. Figure 2C shows that E 2 specifically increased the expression of the Renilla luciferase protein from the pRL-TK-transforming growth factor b 1 (TGFB1), Programmed Cell Death 4 (PDCD4), RAS p21 Protein Activator 1 (RASA1) and RAS Guanyl Nucleotide-Releasing Protein 1 (RASGRP1) reporters in MCF-7 cells, data consistent with miR-21 downregulation by E 2 . In contrast, E 2 did not alter luciferase expression from the putative miR-21 MREs in Cerebral Cavernous Malformations 1 (CCM1) or a member of the RAS oncogene family (RAB6C). Thus, the E 2 -mediated decrease in miR-21 expression (Figure 1 ) resulted in lower amounts of miR-21 available to bind the MRE sequences from the TGFB1, PDCD4, RASA1 and RASGRP1 genes, in turn reducing the targeting of these reporter transcripts for degradation/translational inhibition and thus increasing the amount of Renilla protein and luciferase activity. In contrast, the lack of change in Renilla activity from CCM1 and RAB6C indicates that the MREs in these genes do not appear to be targets of E 2 -induced reduction of miR-21 expression in MCF-7 cells under our assay conditions.
Effect of antisense to miR-21 target gene reporter activity in MCF-7 cells
If the E 2 -induced increase in Renilla luciferase from the MREs of the TGFB1, PDCD4, RASA1 and RASGRP1 genes seen in Figure 2C is due to reduced levels of endogenous miR-21, then transfection of MCF-7 cells with antisense (AS)-miR-21 should have the same effect on luciferase activity. MCF-7 cells were transiently transfected with 2 0 -O-Me-anti-miR-21 (AS-miR-21) ( Figure 2D) . A 92% knockdown of miR-21 expression was achieved ( Figure 5A ). AS-miR-21 resulted in a significant increase in Renilla activity from pRL-TK reporters bearing the miR-21 MREs from the TGFB1, PDCD4, RASA1 and RASGRP1 genes. In contrast, AS-miR-21 did not affect luciferase activity from the putative miR-21 MREs in CCM1 or RAB6C ( Figure 2D ). These data are in agreement with the E 2 responses (Figure 2C) , although E 2 induced higher activity from the RASA1 reporter compared to the ASmiR-21. Overall, these data indicate that these MREs are bone fide targets of miR-21 regulation.
MRE and FL 3'-UTRs activities of PDCD4 and RASA1 in reporter assays in MCF-7 cells
Since sequences flanking the MRE affect miRNA binding and activity (55) , it is important to compare the effect of E 2 and AS-miR-21 in reporters bearing the MRE versus the FL 3 0 UTR of PDCD4 and RASA1 genes ( Figure 2E ). E 2 induced greater luciferase activity from the FL than the PDCD4 MRE. AS-miR-21 increased reporter activity more from the MRE than the FL PDCD4. The AS-miR-21-induced increase in basal luciferase activity was comparable for the MRE and FL RASA1 reporters. AS-mR-21 transfection reduced the fold E 2 -induction for the MRE and FL PDCD4 and RASA1 reporters. The miR-21 knockdown data are consistent with E 2 -ER downregulation of miR-21 increasing reporter activity.
Regulation of primary (pri)-miR-21 promoter activity by E 2 , 4-OHT and ICI 182,780 in MCF-7 cells miR-21 is located in the 10th intron of the TMEM49 gene (56) . To test whether E 2 regulates miR-21 gene expression through the $À1 kb 5 0 flanking region previously reported to function as a promoter for miR-21 (45), transient transfection assays were performed using two constructs: pmiR-21s-luc and pmiR-21as-luc, corresponding to the sense (s) and antisense (as) orientations of this $1 kb region cloned in front of the Firefly luciferase gene (45) ( Figure 3A) . The activity from the pmiR-21as-luc reporter was $2% of that of the pmiR-21s-luc construct, indicating orientation-dependent promoter activity. If E 2 represses miR-21 expression by an interaction of ER with the 5 0 promoter, we should detect a decrease in luciferase reporter activity. E 2 reduced luciferase activity $25% whereas 4-OHT increased pmiR-21 activity by $25% (Figure 3A) . ICI abrogated the inhibition by E 2 , indicating that ER is responsible for reduction in reporter activity. E 2 did not alter TMEM49 transcription ( Figure 3B ). To our knowledge, this is the first examination of the effect of E 2 on TMEM49 transcription. These data are consistent with the independent regulation of TMEM49 and miR-21 in HL-60 cells (56) . Overall, these data agree with the direction, although not magnitude, of changes in endogenous miR-21 expression in response to E 2 , 4-OHT and ICI in MCF-7 cells (Figure 1 ) and indicate that the À1 kb promoter of miR-21 mediates in part, the observed reduction in miR-21 expression by E 2 .
Actinomycin D (ActD) and cycloheximide (CHX) block E 2 -mediated miR-21 expression
To determine whether the E 2 -mediated reduction in miR-21 expression is a direct effect of ER at the genomic level or requires synthesis of a secondary estrogen-responsive protein, MCF-7 cells were pretreated with the transcriptional inhibitor ActD or the protein synthesis inhibitor CHX prior to EtOH or E 2 treatment ( Figure 3C ). Pretreatment with ActD and CHX blocked E 2 -mediated miR-21 repression, indicating that E 2 -repression is mediated by both transcriptional (primary genomic) and secondary mechanisms.
Effect of E 2 , PPT and DPN on endogenous miR-21 target genes in MCF-7 cells
Since E 2 reduced miR-21 expression in MCF-7 cells and increased the expression of miR-21 target reporter gene activity, the effect of E 2 on the mRNA and protein levels of endogenous miR-21-target genes PDCD4, PTEN and BCL2 was examined by Q-PCR ( Figure 4A ) and western blot ( Figure 4B and C) . To determine the relative contribution of the two ER subtypes to these effects, MCF-7 cells were treated with 10 nM PPT or 10 nM DPN, concentrations at which each is an ERa-or ERb-selective agonist, respectively (50) . As expected based on the reporter assay data for PDCD4 in Figure 2 , E 2 increased ÃÃÃ Significantly different from 10 nM E 2 , P < 0.05. (B) E 2 does not affect TMEM49 transcription in MCF-7 cells. miR-21 is encoded within the 10th intron of the TMEM49 gene (56) . MCF-7 cells were treated with EtOH or 10 nM E 2 for 6 h, total RNA was reverse transcribed and Q-PCR was performed. TMEM49 was normalized to 18S. Values are the average AE SEM of triplicate determinations normalized to EtOH. (C) The E 2 -induced decrease in miR-21 expression in MCF-7 cells is mediated in a primary transcriptional/genomic and secondary estrogentarget-dependent manner. MCF-7 cells were pre-treated with stripped medium or stripped medium containing 10 mg/ml ActD or CHX for 1 h before treatment with vehicle control (EtOH), or 10 nM E 2 for 6 h as described in 'Materials and Methods' section. miR-21 expression was determined using Q-PCR as described in 'Materials and Methods' section. The bar graph summarizes the fold change in miR-21 expression relative to no pretreatment (No pretx)-EtOH-treated cells. Ã Significantly different from the EtOH value for each protein, P < 0.01. mRNA ( Figure 4A ) and protein ( Figure 4B and C) levels of PDCD4, results reflecting reduced miR-21 levels (Figure 1 ), thus increased transcript stability. Similar results were observed for BCL2. PPT also increased PDCD4 and BCL2 mRNA and protein levels, whereas DPN reduced PDCD4 and increased BCL2 mRNA levels ( Figure 4A ) while increasing protein amounts ( Figure 4B ). E 2 , PPT and DPN increased PTEN protein but not RNA levels ( Figure 4A and C) , suggesting translational inhibition. Overall, these data indicate roles for both ERa and ERb in mediating the effects of E 2 on miR-21 target gene expression, consistent with results shown in Figure 1 .
EtO H E
AS-miR-21 inhibits endogenous miR-21 target gene protein expression in MCF-7 cells
To confirm the role of downregulation of miR-21 in the increase in protein expression of Pdcd4, PTEN and Bcl-2, MCF-7 cells were transfected with AS-control and AS-miR-21 plasmids followed by treatment with EtOH, E 2 , PPT and DPN for 24 h. If the ER-ligand-induced reduction in miR-21 causes an increase in target protein expression, then the AS-miR-21 should have the same effect. AS-miR-21 reduced miR-21 by 92% ( Figure 5A ). Specific knockdown of miR-21, and not miR-125a or miR-30b, was confirmed by Q-PCR ( Figure 5A ). ASmiR-21 significantly increased the basal Pdcd4, PTEN and Bcl-2 protein expression ( Figure 5B and C) . AS-control did not affect the observed increase in each protein in response to E 2 , PPT and DPN (compare Figures 4B, C and 5B, C). These data indicate that these genes are targets of repression by miR-21. No further increase in protein expression was detected with E 2 or PPT treatment, but DPN significantly increased Pdcd4 and PTEN proteins ( Figure 5C ).
Effect of ERa knock-down on E 2 -induced endogenous miR-21 target gene expression in MCF-7 cells
To confirm the role of ERa in the observed decrease in miR-21 and increase in miR-21-target gene expression in response to E 2 and PPT, MCF-7 cells were transfected with siRNA targeting ERa or control siRNA for 48 h and then treated with EtOH, 10 nM E 2 , PPT, or DPN for 6 h. Transfection of MCF-7 cells with siRNA for ERa reduced ERa mRNA expression by $62% (Supplementary Figure 3) and ERa protein by 61%. In contrast, ERb protein levels were unaffected ( Figure 6A , see also Supplementary Figure 4) . siERa blocked the E 2 -induced repression of miR-21 ( Figure 6B ). Concordantly, knockdown of ERa reduced the E 2 -stimulated expression of miR-21 target genes PDCD4, PTEN and BCL2 ( Figure 6C ). To confirm these findings at the protein level, western blots were performed using antibodies commercially available for Pdcd4, PTEN and Bcl-2 ( Figure 6D ). Results confirm that ERa knockdown reduced the E 2 -and PPT-induced protein expression of the miR-21 target genes PDCD4, PTEN and BCL2 to basal levels ( Figure 6E ). siERa also reduced DPNstimulated expression of Pdcd4, PTEN and Bcl-2 proteins suggesting that at least part of the DPN response may be ERa-mediated.
Effect of ERb knock-down on miR-21 expression in MCF-7 cells
To examine ERb's role in mediating E 2 -suppression of miR-21 transcription, MCF-7 cells were transfected with siRNA targeting ERb or control siRNA for 48 h and then treated with EtOH or 10 nM E 2 for 6 h. siERb reduced ERb mRNA expression by $70% and protein by 64% (Supplementary Figure 5A and B) . Knockdown of ERb reduced basal miR-21 by 73% and E 2 treatment had no further effect ( Figure 6F ). siERb resulted in a commensurate increase in basal PDCD4, PTEN and BCL2 mRNA and a loss of E 2 , DPN and PPT-stimulated PDCD4 and BCL2 transcription (Supplementary Figure 5C and Figure 4 ). With ERb knockdown, PPT and DPN increased PTEN mRNA (Supplementary Figure 5C) .
DISCUSSION
Since the oncomiR miR-21 was the most significantly up-regulated miRNA in breast tumor biopsies compared to normal breast tissue (37) and because estrogen stimulates breast tumorigenesis, the goal of this study was to determine if E 2 regulates the expression of miR-21 in MCF-7 cells as an established human breast cancer model of estrogen responses. To our knowledge, this is the first report that E 2 downregulates miR-21 and thus upregulates the protein expression of miR-21 target genes PDCD4, PTEN and BCL2 in MCF-7 human breast cancer cells. Furthermore, the ability of 4-OHT, ICI and siERa to block the E 2 repression of miR-21 and the subsequent increase in Pdcd4, Pten and Bcl-2 proteins provide a mechanism for the E 2 effect, i.e. through ERa activation. ERb appears to regulate basal miR-21 expression in MCF-7 cells since knockdown of ERb reduced miR-21 expression. ERb represses/opposes ERa transcriptional activity and E 2 -induced cell proliferation (57) (58) (59) (60) (61) . Stable transfection of MCF-7 cells with ERb inhibited xenograft tumor growth, indicating that ERb is a tumor suppressor (62) . We observed that ERb knock down reduced basal miR-21 and there was no further reduction in miR-21 expression with E 2 treatment. These data appear to indicate a relief of repression of ERa's inhibition of miR-21 transcription. Figure 7 shows a schematic model illustrating ER regulation of miR-21 and miR-21 regulation of its targets. Our results showing that E 2 reduces miR-21 expression in MCF-7 are in agreement with recent reports that E 2 down-regulated miR-21 in endometrial stromal cells (63) and in the uterus of ovariectomized mice (64) . At the same time, given the established link between estrogen and breast carcinogenesis (65, 66) , one might expect E 2 to upregulate miR-21 rather than inhibit miR-21 as shown here. Likewise, the increase in miR-21 expression by 4-OHT appears to contradict its anticipated anti-tumor role, but is consistent with 4-OHT's genespecific SERM activity as indicated by its activity opposing E 2 's inhibition of miR-21 expression. For complex phenotypes including cell proliferation, genes and proteins are up-and down-regulated by a variety of interacting mechanisms that we are only beginning to understand and integrate. Our data are supported by a recent report showing that miR-21 expression was reduced in TAMresistant MCF-7 cells (67), a finding likely reflecting the loss of ER-regulated responses in TAM-resistant cells. It is well-established that E 2 and 4-OHT regulate transcription in a gene-and cell-specific manner (68) (69) (70) (71) (72) and the findings reported here add miR-21 to the list of ER-regulated genes. We conclude that our apparent 'contradictory data' of E 2 down-regulating and 4-OHT increasing miR-21 expression add unexpected complexity to understanding of E 2 action in breast tumorigenesis.
The reduction of miR-21 expression in response to E 2 appears to be mediated, in part, by the À1kb promoter. However, because the reduction in transcription was only $25% in the reporter assay compared to a $80% reduction by Q-PCR analysis of miR-21 expression, it is possible that additional regions are also important in regulating miR-21 expression in response to E 2 . It has been established that E 2 increases ERa binding to chromosome regions outside gene promoters (73, 74 Figure 6) . AP-1 was shown to activate miR-21 transcription by direct interaction with three binding sites in the miR-21 promoter in response to PMA treatment of HL-60 cells (56) . Although both ERa and ERb interact with AP-1 to regulate gene expression, the direction of regulation (up or down) varies depending on the ligand, cell type, chromatin context and neighboring transcription factor-binding events (77, 78) . Here we showed that E 2 did not alter TMEM49 transcription which supports previous results that TMEM49 and miR-21 are independently regulated (56) . Further studies will be required to analyze the precise mechanisms mediating E 2 repression of miR-21.
Both E 2 and AS-miR-21 induced RASA1 reporter activity; however, the magnitude of luciferase induction was higher with E 2 than AS-miR-21. Although normalized relative luciferase between EtOH versus controlAS transfected cells is an unequal comparison, one possible explanation for this difference is that E 2 alters the expression of other genes or pathways that selectively impact the RASA1 reporter compared to the other reporters, e.g. TGFB1 and PDCD4, that show similar luciferase activity.
Our data showing the downregulation of miR-21 by E 2 correlated with upregulation of PDCD4 RNA and protein ( Figure 4B and C) are in agreement with a report that blocking miR-21 using locked nucleic-acid-modified oligonucleotides increased PDCD4 mRNA and protein in MCF-7 cells (79) . Furthermore, our results in the transient transfection assays indicate that miR-21 regulates PDCD4 by an MRE in the 3 0 UTR. The conclusion that E 2 -increases PDCD4 expression through inhibition of miR-21 expression in MCF-7 cells is further supported by data showing that AS-miR-21 inhibited E 2 -induced Renilla luciferase activity from the PDCD4 MRE and 3 0 -UTR in transfected MCF-7 ( Figure 2B ) and that AS-miR-21 mimics E 2 -induction of Pdcd4 protein ( Figure 5C ). Our ERa knockdown experiments indicate that ERa is responsible for the E 2 -mediated inhibition of miR-21 expression and regulation of PDCD4 as well as other miR-21 target genes. The DPN-induced reduction in PDCD4 mRNA aligns with a report that DPNactivated ERb inhibits the transcription of PPT-activated ERa target genes in human breast cancer cells (57) . The increase seen in Pdcd4 protein after 24 h of DPN treatment may result from a secondary gene effect. miR-21 functions as an oncogene and modulates tumorigenicity through regulation of Bcl-2 in MCF-7 cells (38) . Inhibition of miR-21 expression by AS-miR-21 reduced Bcl-2 protein expression and increased apoptosis in MCF-7 cells in vitro and in tumor xenografts in mice (38) . Consistent with these findings, our data demonstrate that both E 2 and PPT decrease miR-21 and increase BCL2 mRNA and protein expression in MCF-7 cells. BCL2 expression has long been considered a good prognostic marker in breast cancer (80) . DPN increased BCL2 mRNA and protein expression; likely by ERa activation because E 2 regulates BCL2 transcription in MCF-7 cells via ERa-Sp1 and AP1 interactions (81), we can not conclude that the increase in BCL2 mRNA is due solely to E 2 -mediated decreased miR-21. Further studies will be needed to dissect the relative contributions of multiple ERa-mediated pathways controlling BCL2 gene expression.
PTEN is an important tumor suppressor (82) that has been identified as a breast cancer susceptibility gene (83) . miR-21 regulates PTEN in human hepatocellular cancer cells and tumors (35, 84) but to our knowledge, no one has examined miR-21 regulation of PTEN in breast cancer. We found that E 2 , PPT and DPN increased PTEN protein levels without affecting PTEN transcript levels (Figure 4) , indicating translational inhibition. Knockdown of ERa by siRNA blocked the E 2 -mediated downregulation of miR-21 and the E 2 -induced increase in PTEN, indicating that this effect is mediated via ERa, and commensurate with downregulation of miR-21. With ERb knockdown, PPT and DPN increased PTEN mRNA; however, because E 2 , PPT and DPN did not regulate PTEN mRNA in MCF-7 cells, it is likely that this increase is mediated by the loss of the expression of another PTEN transcriptional repressor with ERb knockdown. Our data contradict a previous report showing no alteration of PTEN expression in MCF-7 cells treated with 100 nM E 2 for 24 h (85). This difference may be due to the lower, physiologically relevant E 2 concentration and shorter treatment time used here.
In summary, we report for the first time that miR-21 is down-regulated in response to E 2 in an ERa-dependent manner and that ERb regulates basal miR-21 expression. Furthermore, this inhibition correlates with up-regulation of miR-21 targets: PDCD4, PTEN and Bcl-2. The identification of miR-21 as a miRNA regulated by ER may open new avenues for potential therapeutic intervention in breast cancer treatment.
